IRImmediate releaseUnder development — not offered for commercial distribution
Dabigatran Etexilate Immediate Release Pellets
Active ingredient Dabigatran Etexilate Mesylate
Immediate release multiparticulate pellets under development pipeline.
Supply form: semi-finished, ready-to-fill pellets. Not for direct patient dispensing.
Formulation and monograph
- Potency / drug load
- 35.0% & 40.0% w/w
- Validated strengths
- 35.0%, 40.0% w/w
- Pharmacopoeia
- USP / In-house monograph
Packaging and storage
- Primary moisture barrier: double virgin polyethylene liners, heat-sealed, with pharmaceutical-grade silica gel desiccants.
- Secondary pack: tamper-evident HDPE drums suitable for domestic transport or export freight.
- Store protected from direct sunlight and humidity, at the temperature specified by the active-substance monograph.
